Last reviewed · How we verify
ibuprofen and codeine
Ibuprofen and codeine, marketed by St. Justine's Hospital, is a combination analgesic currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports its competitive position. The primary risk is the potential increase in generic competition following the patent expiry in 2028.
At a glance
| Generic name | ibuprofen and codeine |
|---|---|
| Also known as | advil, motrin |
| Sponsor | St. Justine's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial (PHASE4)
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial (PHASE2)
- Opioid Use After Laparoscopic Salpingectomy (PHASE4)
- Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction (PHASE1)
- Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures (PHASE4)
- Supracondylar Post-Operative Pain Study (PHASE4)
- ICE-T Pain Regimen for Total Laparoscopic Hysterectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ibuprofen and codeine CI brief — competitive landscape report
- ibuprofen and codeine updates RSS · CI watch RSS
- St. Justine's Hospital portfolio CI